Unknown

Dataset Information

0

Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators.


ABSTRACT: Immune-complexes play an important role in the inflammatory diseases of the lung. Neutrophil activation mediates immune-complex (IC) deposition-induced acute lung injury (ALI). Components of gamma amino butyric acid (GABA) signaling, including GABA B receptor 2 (GABABR2), GAD65/67 and the GABA transporter, are present in the lungs and in the neutrophils. However, the role of pulmonary GABABR activation in the context of neutrophil-mediated ALI has not been determined. Thus, the objective of the current study was to determine whether administration of a GABABR agonist, baclofen would ameliorate or exacerbate ALI. We hypothesized that baclofen would regulate IC-induced ALI by preserving pulmonary GABABR expression. Rats were subjected to sham injury or IC-induced ALI and two hours later rats were treated intratracheally with saline or 1 mg/kg baclofen for 2 additional hours and sacrificed. ALI was assessed by vascular leakage, histology, TUNEL, and lung caspase-3 cleavage. ALI increased total protein, tumor necrosis factor ? (TNF-? and interleukin-1 receptor associated protein (IL-1R AcP), in the bronchoalveolar lavage fluid (BALF). Moreover, ALI decreased lung GABABR2 expression, increased phospho-p38 MAPK, promoted I?B degradation and increased neutrophil influx in the lung. Administration of baclofen, after initiation of ALI, restored GABABR expression, which was inhibited in the presence of a GABABR antagonist, CGP52432. Baclofen administration activated pulmonary phospho-ERK and inhibited p38 MAPK phosphorylation and I?B degradation. Additionally, baclofen significantly inhibited pro-inflammatory TNF-? and IL-1?AcP release and promoted BAL neutrophil apoptosis. Protective effects of baclofen treatment on ALI were possibly mediated by inhibition of TNF-?- and IL-1?-mediated inflammatory signaling. Interestingly, GABABR2 expression was regulated in the type II pneumocytes in lung tissue sections from lung injured patients, further suggesting a physiological role for GABABR2 in the repair process of lung damage. GABABR2 agonists may play a potential therapeutic role in ALI.

SUBMITTER: Jin S 

PROVIDER: S-EPMC4388838 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators.

Jin Shunying S   Merchant Michael L ML   Ritzenthaler Jeffrey D JD   McLeish Kenneth R KR   Lederer Eleanor D ED   Torres-Gonzalez Edilson E   Fraig Mostafa M   Barati Michelle T MT   Lentsch Alex B AB   Roman Jesse J   Klein Jon B JB   Rane Madhavi J MJ  

PloS one 20150407 4


Immune-complexes play an important role in the inflammatory diseases of the lung. Neutrophil activation mediates immune-complex (IC) deposition-induced acute lung injury (ALI). Components of gamma amino butyric acid (GABA) signaling, including GABA B receptor 2 (GABABR2), GAD65/67 and the GABA transporter, are present in the lungs and in the neutrophils. However, the role of pulmonary GABABR activation in the context of neutrophil-mediated ALI has not been determined. Thus, the objective of the  ...[more]

Similar Datasets

| S-EPMC7947684 | biostudies-literature
2010-05-15 | GSE21326 | GEO
| S-EPMC3696655 | biostudies-literature
| S-EPMC9962762 | biostudies-literature
| S-EPMC4939094 | biostudies-literature
| S-EPMC4516894 | biostudies-literature
| S-EPMC10025757 | biostudies-literature
| S-EPMC5437126 | biostudies-literature
| S-EPMC1308852 | biostudies-literature
| S-EPMC2994245 | biostudies-literature